Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Subscribe To Our Newsletter & Stay Updated